(Q40433020)

20 September 2017

title

Sublingual-swallow immunotherapy with standardized 3-grass pollen extract: a double-blind, placebo-controlled study (English)

1 reference

20 September 2017

0 references

0 references

1 reference

Frédéric de Blay

1

1 reference

20 September 2017

Cindy Barnig

2

1 reference

20 September 2017

Gisèle Kanny

3

1 reference

20 September 2017

Ashok Purohit

4

1 reference

20 September 2017

Francisque Leynadier

5

1 reference

20 September 2017

J Manuel Tunon de Lara

6

1 reference

20 September 2017

Habib Chabane

7

1 reference

20 September 2017

Laurence Guérin

8

1 reference

20 September 2017

SUBLIM Group

9

1 reference

20 September 2017

publication date

1 November 2007

1 reference

Annals of Allergy, Asthma & Immunology

20 September 2017

published in

1 reference

20 September 2017

volume

99

1 reference

20 September 2017

issue

5

1 reference

20 September 2017

page(s)

453-461

1 reference

Allergic rhinitis and its impact on asthma

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960571-6

7 January 2021

Long-term risk factors for developing asthma and allergic rhinitis: a 23-year follow-up study of college students.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960571-6

7 January 2021

Development and validation of the mini Rhinoconjunctivitis Quality of Life Questionnaire.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960571-6

7 January 2021

Methodology and quality of immunotherapy trials

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960571-6

7 January 2021

Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960571-6

7 January 2021

Randomized controlled trial of high-dose sublingual immunotherapy to treat seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960571-6

7 January 2021

Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960571-6

7 January 2021

Post-marketing surveillance study on the safety of sublingual immunotherapy in pediatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960571-6

7 January 2021

Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960571-6

7 January 2021

Sublingual-swallow immunotherapy (SLIT) with a standardized five-grass-pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960571-6

7 January 2021

Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960571-6

7 January 2021

Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960571-6

7 January 2021

Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960571-6

7 January 2021

A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960571-6

7 January 2021

Quantitative assessment of the adherence to sublingual immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960571-6

7 January 2021

Determinants of patient compliance with allergen immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960571-6

7 January 2021

10.1016/S1081-1206(10)60571-6

Identifiers

DOI

1 reference

20 September 2017

1 reference